Quick Answer
Sionna Therapeutics, Inc. reported R&D Expense of $60.26 million for fiscal year 2025.
Sionna Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $60.26M | +5.2% |
| 2024 | $57.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $16.04M | -34.7% | +4.3% |
| June 30, 2025 | $15.38M | +86.8% | +12.5% |
| March 31, 2025 | $13.67M | +33.7% | -44.4% |
| September 30, 2024 | $24.58M | — | +198.6% |
| June 30, 2024 | $8.23M | — | -19.4% |
| March 31, 2024 | $10.22M | — | — |
- Sionna Therapeutics, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Sionna Therapeutics, Inc.’s r&d expense has grown by 5.2% (from $57.29 million to $60.26 million).
- The most recent figure is from Sionna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: